Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

52°
- Benton, AR (72018)
  Today
  
  Cloudy skies. High 59F. Winds NE at 5 to 10 mph..
  
  Tonight
  
  Cloudy. Low 42F. Winds NE at 5 to 10 mph.
  
  Updated: January 2, 2026 @ 11:49 am
- Full Forecast

- Site search

Home
News
- Local News
Sports
Obituaries
Multimedia
- Photo Galleries
- Videos
e-Edition
Classifieds
Archives
Readers Choice 2025

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

1.985 -0.065 (-3.17%)

Streaming Delayed Price Updated: 1:27 PM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Editas (EDIT) Q2 2024 Earnings Call Transcript ↗

November 27, 2025

Editas (EDIT) Q2 2024 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Editas Medicine Inc (NASDAQ:EDIT) Beats Q3 2025 Estimates and Provides Key Pipeline Update ↗

November 10, 2025

Editas Medicine beats Q3 2025 earnings estimates, reports strong revenue growth, and advances its lead gene-editing program, EDIT-401.

Via Chartmill

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

November 10, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures

November 06, 2025

A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as...

Via TokenRing AI

Topics Artificial Intelligence Climate Change Intellectual Property

Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

November 03, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles ↗

October 27, 2025

Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event.

Via Benzinga

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

October 09, 2025

Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse models

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine Inc (NASDAQ:EDIT) Shows High Growth Momentum and Strong Technical Trend ↗

October 07, 2025

Editas Medicine (EDIT) stock shows strong technical uptrends and explosive 597% revenue growth, making it a top pick for momentum investors.

Via Chartmill

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

October 06, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗

September 18, 2025

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.

Via Benzinga

Editas Medicine Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

September 05, 2025

Via Benzinga

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

September 02, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

August 28, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

Editas Medicine to Participate in Upcoming Investor Conferences

August 27, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

Why Editas Medicine Stock Was Skyrocketing This Week ↗

August 15, 2025

The company's CEO made quite the encouraging statement regarding its immediate future.

Via The Motley Fool

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

August 13, 2025

Via Benzinga

Top movers in Wednesday's session ↗

August 13, 2025

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Wednesday's session: gap up and gap down stocks ↗

August 13, 2025

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.

Via Chartmill

Editas Medicine Inc (NASDAQ:EDIT) Reports Mixed Q2 2025 Earnings: Revenue Beat but Wider Loss ↗

August 12, 2025

Editas Medicine posted Q2 2025 revenue of $3.58M, beating estimates, but EPS loss widened to -$0.63. Stock dipped 1.75% amid restructuring concerns. Pipeline progress includes IND filing plans for...

Via Chartmill

Editas Medicine Announces Second Quarter 2025 Results and Business Updates

August 12, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

Can This Beaten-Down Stock Bounce Back? ↗

August 12, 2025

This small-cap biotech is seeking to develop breakthrough therapies, but so far it's found little success.

Via The Motley Fool

Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now? ↗

June 28, 2025

Via The Motley Fool

Topics Workforce

2 Beaten-Down Stocks to Avoid ↗

June 27, 2025

Via The Motley Fool

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst ↗

June 18, 2025

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

Via Benzinga

Editas Medicine Is Great. Here's Why You Shouldn't Buy It. ↗

June 17, 2025

Via The Motley Fool

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover ↗

June 17, 2025

The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments.

Via Investor's Business Daily

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

June 12, 2025

From Editas Medicine, Inc.

Via GlobeNewswire

1 Stock Down 97% That Could Double, According to Wall Street ↗

May 25, 2025

Via The Motley Fool

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

May 21, 2025

Via Benzinga

Editas Medicine: A Cautionary Tale for Investors ↗

May 15, 2025

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Entertainment
Local Events
Obituaries
Multimedia
Announcements
e-Edition
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

bentoncourier.com
321 North Market Street
Benton, AR 72018
Phone: 501-315-8228
Email: bcadmin@bentoncourier.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Benton, AR (72018)

Today

Tonight

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

All News about Editas Medicine, Inc. - Common Stock

Sections

Services

Follow Us